Tag

Bms

All articles tagged with #bms

healthcare1 month ago•3 min saved

Autoimmune CAR-T Trials Halt After Fatal IEC-HS Events

Novartis has temporarily paused its autologous CD19 CAR-T program for autoimmune diseases after three IEC-HS–related deaths, affecting multiple phase 1/2 studies across lupus, systemic sclerosis, ANCA-associated vasculitis, myopathies and other conditions, with patient monitoring continuing. Bristol Myers Squibb has also paused enrollment in its autologous CD19 zola-cel autoimmune trials due to transient inflammatory events, though oncology programs remain active. Analysts suggest rapid manufacturing platforms (T-Charge, NEXT-T) may drive increased T‑cell expansion and toxicities, prompting a cautious safety review before resumption.

via Fierce Biotech|

#autoimmune-diseases #bms #car-t-therapy

technology2 months ago•1 min saved

BMS, Nvidia push to build life sciences’ most powerful AI engine

Bristol Myers Squibb is expanding its Nvidia-powered infrastructure with the DGX SuperPOD to create what it calls the most powerful, energy-efficient AI platform in life sciences, enabling hybrid human-AI science to accelerate R&D and improve decision quality across its pipeline; the move extends a multi-year collaboration with Nvidia and aligns with other pharma AI partnerships in the sector.

via Fierce Biotech|

#ai #bms #drug-discovery

business5 months ago•2 min saved

BMS inks $15B China-backed deal to fast-track Hengrui assets

Bristol Myers Squibb is striking a broad deal with Hengrui Pharma worth up to $15.2 billion, featuring $600 million upfront for 13 early-stage programs, ex-China rights to four oncology/hematology assets, and joint discovery on five candidates; Hengrui will gain access to BMS immunology assets in China, Hong Kong and Macau and lead early development to proof of concept, in a move that leverages China's reportedly faster timelines (50–70% quicker) to clinical proof of concept.

via Fierce Biotech|

#biotech #bms #business